A drug ‘R’ producing no response by itself causes the log dose-response curve of another drug ‘S’ to shift to the right in a parallel manner without decreasing the maximal response: Drug ‘R’ is a: A. Partial agonist B. Inverse agonist C. Competitive antagonist D. Noncompetitive antagonist

A drug ‘R’ producing no response by itself causes the log dose-response curve of another drug ‘S’ to shift to the right in a parallel manner without decreasing the maximal response: Drug ‘R’ is a: A. Partial agonist B. Inverse agonist C. Competitive antagonist D. Noncompetitive antagonist
by

1 Answer

Answer :

C. Competitive antagonist
by

Related questions

A drug ‘R’ producing no response by itself causes the log dose-response curve of another drug ‘S’ to shift to the right in a parallel manner without decreasing the maximal response: Drug ‘R’ is a: A. Partial agonist B. Inverse agonist C. Competitive antagonist D. Noncompetitive antagonist

Description : A drug ‘R’ producing no response by itself causes the log dose-response curve of another drug ‘S’ to shift to the right in a parallel manner without decreasing the maximal response: Drug ‘R’ is a: A. Partial agonist B. Inverse agonist C. Competitive antagonist D. Noncompetitive antagonist

Last Answer : C. Competitive antagonist

A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Description : A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Last Answer : C. Noncompetitive antagonist

A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Description : A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Last Answer : C. Noncompetitive antagonist

The following is not a feature of competitive antagonists: A. Chemical resemblance with the agonist B. Parallel rightward shift of the agonist log doseresponse curve C. Suppression of maximal agonist response D. Apparent reduction in agonist affinity for the receptor

Description : The following is not a feature of competitive antagonists: A. Chemical resemblance with the agonist B. Parallel rightward shift of the agonist log doseresponse curve C. Suppression of maximal agonist response D. Apparent reduction in agonist affinity for the receptor

Last Answer : C. Suppression of maximal agonist response

The following is not a feature of competitive antagonists: A. Chemical resemblance with the agonist B. Parallel rightward shift of the agonist log doseresponse curve C. Suppression of maximal agonist response D. Apparent reduction in agonist affinity for the receptor

Description : The following is not a feature of competitive antagonists: A. Chemical resemblance with the agonist B. Parallel rightward shift of the agonist log doseresponse curve C. Suppression of maximal agonist response D. Apparent reduction in agonist affinity for the receptor

Last Answer : C. Suppression of maximal agonist response

The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists

Description : The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists

Last Answer : B. It is a rectangular hyperbola

The following is a competitive antagonist of GABA but a noncompetitive antagonist of diazepam: A. Picrotoxin B. Muscimol C. Flumazenil D. Bicuculline

Description : The following is a competitive antagonist of GABA but a noncompetitive antagonist of diazepam: A. Picrotoxin B. Muscimol C. Flumazenil D. Bicuculline

Last Answer : D. Bicuculline

The following is a competitive antagonist of GABA but a noncompetitive antagonist of diazepam: A. Picrotoxin B. Muscimol C. Flumazenil D. Bicuculline

Description : The following is a competitive antagonist of GABA but a noncompetitive antagonist of diazepam: A. Picrotoxin B. Muscimol C. Flumazenil D. Bicuculline

Last Answer : D. Bicuculline

The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists

Description : The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists

Last Answer : B. It is a rectangular hyperbola

‘Drug efficacy’ refers to: A. The range of diseases in which the drug is beneficial B. The maximal intensity of response that can be produced by the drug C. The dose of the drug needed to produce half maximal effect D. The dose of the drug needed to produce therapeutic effect

Description : ‘Drug efficacy’ refers to: A. The range of diseases in which the drug is beneficial B. The maximal intensity of response that can be produced by the drug C. The dose of the drug needed to produce half maximal effect D. The dose of the drug needed to produce therapeutic effect

Last Answer : B. The maximal intensity of response that can be produced by the drug

‘Drug efficacy’ refers to: A. The range of diseases in which the drug is beneficial B. The maximal intensity of response that can be produced by the drug C. The dose of the drug needed to produce half maximal effect D. The dose of the drug needed to produce therapeutic effect

Description : ‘Drug efficacy’ refers to: A. The range of diseases in which the drug is beneficial B. The maximal intensity of response that can be produced by the drug C. The dose of the drug needed to produce half maximal effect D. The dose of the drug needed to produce therapeutic effect

Last Answer : B. The maximal intensity of response that can be produced by the drug

Which of the following terms best describes the antagonism of leukotriene’s bronchoconstrictor effect (mediated at leukotriene receptors) by terbutaline (acting a adrenoceptors) in a patient with asthma? (a) Pharmacologic antagonist (b) Partial agonist (c) Physiologic antagonist (d) Chemical antagonist (e) Noncompetitive antagonist

Description : Which of the following terms best describes the antagonism of leukotriene's bronchoconstrictor effect (mediated at leukotriene receptors) by terbutaline (acting a adrenoceptors) in a patient with ... ) Partial agonist (c) Physiologic antagonist (d) Chemical antagonist (e) Noncompetitive antagonist

Last Answer : Ans: C

If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Description : If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Last Answer : D. Highly selective

If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Description : If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Last Answer : D. Highly selective

The following statement is not true of ‘potency’ of a drug: A. Refers to the dose of the drug needed to produce a certain degree of response B. Can be related to that of its congeners by the relative position of its dose-response curve on the dose axis C. It is often not a major consideration in the choice of a drug D. It reflects the capacity of the drug to produce a drastic response

Description : The following statement is not true of potency' of a drug: A. Refers to the dose of the drug needed to produce a certain degree of response B. Can be related to that of its congeners by ... consideration in the choice of a drug D. It reflects the capacity of the drug to produce a drastic response

Last Answer : D. It reflects the capacity of the drug to produce a drastic response

The following statement is not true of ‘potency’ of a drug: A. Refers to the dose of the drug needed to produce a certain degree of response B. Can be related to that of its congeners by the relative position of its dose-response curve on the dose axis C. It is often not a major consideration in the choice of a drug D. It reflects the capacity of the drug to produce a drastic response

Description : The following statement is not true of potency' of a drug: A. Refers to the dose of the drug needed to produce a certain degree of response B. Can be related to that of its congeners by ... consideration in the choice of a drug D. It reflects the capacity of the drug to produce a drastic response

Last Answer : D. It reflects the capacity of the drug to produce a drastic response

Study of drug-receptor interaction has now shown that: A. Maximal response occurs only when all receptors are occupied by the drug B. Drugs exert an ‘all or none’ action on a receptor C. Receptor and drugs acting on it have rigid complementary ‘lock and key’ structural features D. Properties of ‘affinity’ and ‘intrinsic activity’ are independently variable

Description : Study of drug-receptor interaction has now shown that: A. Maximal response occurs only when all receptors are occupied by the drug B. Drugs exert an all or none' action on a ... lock and key' structural features D. Properties of affinity' and intrinsic activity' are independently variable

Last Answer : D. Properties of ‘affinity’ and ‘intrinsic activity’ are independently variable

Study of drug-receptor interaction has now shown that: A. Maximal response occurs only when all receptors are occupied by the drug B. Drugs exert an ‘all or none’ action on a receptor C. Receptor and drugs acting on it have rigid complementary ‘lock and key’ structural features D. Properties of ‘affinity’ and ‘intrinsic activity’ are independently variable

Description : Study of drug-receptor interaction has now shown that: A. Maximal response occurs only when all receptors are occupied by the drug B. Drugs exert an all or none' action on a ... lock and key' structural features D. Properties of affinity' and intrinsic activity' are independently variable

Last Answer : D. Properties of ‘affinity’ and ‘intrinsic activity’ are independently variable

A partial agonist can antagonise the effects of a full agonist because it has: A. High affinity but low intrinsic activity B. Low affinity but high intrinsic activity C. No affinity and low intrinsic activity D. High affinity but no intrinsic activity

Description : A partial agonist can antagonise the effects of a full agonist because it has: A. High affinity but low intrinsic activity B. Low affinity but high intrinsic activity C. No affinity and low intrinsic activity D. High affinity but no intrinsic activity

Last Answer : A. High affinity but low intrinsic activity

A partial agonist can antagonise the effects of a full agonist because it has: A. High affinity but low intrinsic activity B. Low affinity but high intrinsic activity C. No affinity and low intrinsic activity D. High affinity but no intrinsic activity

Description : A partial agonist can antagonise the effects of a full agonist because it has: A. High affinity but low intrinsic activity B. Low affinity but high intrinsic activity C. No affinity and low intrinsic activity D. High affinity but no intrinsic activity

Last Answer : A. High affinity but low intrinsic activity

In addition to slow intravenous infusion, which of the following routes of administration allows for titration of the dose of a drug with the response: A. Sublingual B. Transdermal C. Inhalational D. Nasal insufflation

Description : In addition to slow intravenous infusion, which of the following routes of administration allows for titration of the dose of a drug with the response: A. Sublingual B. Transdermal C. Inhalational D. Nasal insufflation

Last Answer : C. Inhalational

In addition to slow intravenous infusion, which of the following routes of administration allows for titration of the dose of a drug with the response: A. Sublingual B. Transdermal C. Inhalational D. Nasal insufflation

Description : In addition to slow intravenous infusion, which of the following routes of administration allows for titration of the dose of a drug with the response: A. Sublingual B. Transdermal C. Inhalational D. Nasal insufflation

Last Answer : C. Inhalational

Losartan is a: A. Selective AT1 receptor antagonist B. Selective AT2 receptor antagonist C. Nonselective AT1 + AT2 receptor antagonist D. AT1 receptor partial agonist

Description : Losartan is a: A. Selective AT1 receptor antagonist B. Selective AT2 receptor antagonist C. Nonselective AT1 + AT2 receptor antagonist D. AT1 receptor partial agonist

Last Answer : A. Selective AT1 receptor antagonist

A drug which is generally administered in standard doses without the need for dose individualization is: A. Insulin B. Mebendazole C. Prednisolone D. Digoxin

Description : A drug which is generally administered in standard doses without the need for dose individualization is: A. Insulin B. Mebendazole C. Prednisolone D. Digoxin

Last Answer : B. Mebendazole

The antidotal action of sodium nitrite in cyanide poisoning is based on: A. Physical antagonism B. Chemical antagonism C. Physiological antagonism D. Noncompetitive antagonism

Description : The antidotal action of sodium nitrite in cyanide poisoning is based on: A. Physical antagonism B. Chemical antagonism C. Physiological antagonism D. Noncompetitive antagonism

Last Answer : B. Chemical antagonism

The antidotal action of sodium nitrite in cyanide poisoning is based on: A. Physical antagonism B. Chemical antagonism C. Physiological antagonism D. Noncompetitive antagonism

Description : The antidotal action of sodium nitrite in cyanide poisoning is based on: A. Physical antagonism B. Chemical antagonism C. Physiological antagonism D. Noncompetitive antagonism

Last Answer : B. Chemical antagonism

What is true in relation to drug receptors: A. All drugs act through specific receptors B. All drug receptors are located on the surface of the target cells C. Agonists induce a conformational change in the receptor D. Partial agonists have low affinity for the receptor

Description : What is true in relation to drug receptors: A. All drugs act through specific receptors B. All drug receptors are located on the surface of the target cells C. Agonists induce a conformational change in the receptor D. Partial agonists have low affinity for the receptor

Last Answer : C. Agonists induce a conformational change in the receptoR

What is true in relation to drug receptors: A. All drugs act through specific receptors B. All drug receptors are located on the surface of the target cells C. Agonists induce a conformational change in the receptor D. Partial agonists have low affinity for the receptor

Description : What is true in relation to drug receptors: A. All drugs act through specific receptors B. All drug receptors are located on the surface of the target cells C. Agonists induce a conformational change in the receptor D. Partial agonists have low affinity for the receptor

Last Answer : C. Agonists induce a conformational change in the receptor

Choose the correct statement about allopurinol: A. It is a purine antimetabolite with antineoplastic activity B. It is a competitive inhibitor of xanthine oxidase C. It is inactive itself, but its metabolite alloxanthine is a competitive inhibitor of xanthine oxidase D. Both allopurinol as well as its metabolite alloxanthine are noncompetitive inhibitors of xanthine oxidase

Description : Choose the correct statement about allopurinol: A. It is a purine antimetabolite with antineoplastic activity B. It is a competitive inhibitor of xanthine oxidase C. It is inactive itself ... D. Both allopurinol as well as its metabolite alloxanthine are noncompetitive inhibitors of xanthine oxidase

Last Answer : B. It is a competitive inhibitor of xanthine oxidase

Reflex bronchoconstriction is most likely to occur with the following form of inhaled antiasthma medication: A. Metered dose spray of drug in solution B. Dry powder rotacap C. Nebuliser D. Nebuliser with spacer

Description : Reflex bronchoconstriction is most likely to occur with the following form of inhaled antiasthma medication: A. Metered dose spray of drug in solution B. Dry powder rotacap C. Nebuliser D. Nebuliser with spacer

Last Answer : B. Dry powder rotacap

A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Description : A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Last Answer : B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication

The therapeutic index of a drug is a measure of its: A. Safety B. Potency C. Efficacy D. Dose variability

Description : The therapeutic index of a drug is a measure of its: A. Safety B. Potency C. Efficacy D. Dose variability

Last Answer : A. Safety

The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Description : The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Last Answer : C. Volume of distribution

When the same dose of a drug is repeated at half life intervals, the steady-state (plateau) plasma drug concentration is reached after: A. 2–3 half lives B. 4–5 half lives C. 6–7 half lives D. 8–10 half lives

Description : When the same dose of a drug is repeated at half life intervals, the steady-state (plateau) plasma drug concentration is reached after: A. 2–3 half lives B. 4–5 half lives C. 6–7 half lives D. 8–10 half lives

Last Answer : B. 4–5 half lives

If the clearance of a drug remains constant, doubling the dose rate will increase the steady-state plasma drug concentration by a factor of: A. × 3 B. × 2 C. × 1.5 D. × 1.3

Description : If the clearance of a drug remains constant, doubling the dose rate will increase the steady-state plasma drug concentration by a factor of: A. × 3 B. × 2 C. × 1.5 D. × 1.3

Last Answer : B. × 2

Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to that excreted in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Description : Tricyclic antidepressants can alter the oral absorption of many drugs by: A. Complexing with the other drug in the intestinal lumen B. Altering gut motility C. Altering gut flora D. Damaging gut mucosa

Last Answer : C. Altering gut flora

Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to that excreted in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Description : Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to ... in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Last Answer : A. Percentage of administered dose that reaches systemic circulation in the unchanged form

A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Description : A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Last Answer : B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication

A fixed dose combination preparation meant for internal use must not contain the following class of drug: A. Thiazide diuretic B. Fluoroquinolone antimicrobial C. Corticosteroid D. H2 blocker

Description : A fixed dose combination preparation meant for internal use must not contain the following class of drug: A. Thiazide diuretic B. Fluoroquinolone antimicrobial C. Corticosteroid D. H2 blocker

Last Answer : C. Corticosteroid

The therapeutic index of a drug is a measure of its: A. Safety B. Potency C. Efficacy D. Dose variability

Description : The therapeutic index of a drug is a measure of its: A. Safety B. Potency C. Efficacy D. Dose variability

Last Answer : A. Safety

The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Description : The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Last Answer : C. Volume of distribution

When the same dose of a drug is repeated at half life intervals, the steady-state (plateau) plasma drug concentration is reached after: A. 2–3 half lives B. 4–5 half lives C. 6–7 half lives D. 8–10 half lives

Description : When the same dose of a drug is repeated at half life intervals, the steady-state (plateau) plasma drug concentration is reached after: A. 2–3 half lives B. 4–5 half lives C. 6–7 half lives D. 8–10 half lives

Last Answer : B. 4–5 half lives

If the clearance of a drug remains constant, doubling the dose rate will increase the steady-state plasma drug concentration by a factor of: A. × 3 B. × 2 C. × 1.5 D. × 1.3

Description : If the clearance of a drug remains constant, doubling the dose rate will increase the steady-state plasma drug concentration by a factor of: A. × 3 B. × 2 C. × 1.5 D. × 1.3

Last Answer : B. × 2

If a drug has a constant bioavailability and first order elimination, its maintenance dose rate will be directly proportional to its: A. Volume of distribution B. Plasma protein binding C. Lipid solubility D. Total body clearance

Description : If a drug has a constant bioavailability and first order elimination, its maintenance dose rate will be directly proportional to its: A. Volume of distribution B. Plasma protein binding C. Lipid solubility D. Total body clearance

Last Answer : D. Total body clearanc

If a drug is eliminated by first order kinetics: A. A constant amount of the drug will be eliminated per unit time B. Its clearance value will remain constant C. Its elimination half life will increase with dose D. It will be completely eliminated from the body in 2 × half life period

Description : If a drug is eliminated by first order kinetics: A. A constant amount of the drug will be eliminated per unit time B. Its clearance value will remain constant C. Its elimination half life will increase with dose D. It will be completely eliminated from the body in 2 × half life period

Last Answer : B. Its clearance value will remain constant

Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to that excreted in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Description : Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to ... in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Last Answer : A. Percentage of administered dose that reaches systemic circulation in the unchanged form

Agonist induced autophosphorylation, internalization and down regulation is a distinctive feature of: A. G-protein coupled receptors B. Intrinsic ion channel containing receptors C. Tyrosine protein kinase receptors D. Receptors regulating gene expression

Description : Agonist induced autophosphorylation, internalization and down regulation is a distinctive feature of: A. G-protein coupled receptors B. Intrinsic ion channel containing receptors C. Tyrosine protein kinase receptors D. Receptors regulating gene expression

Last Answer : C. Tyrosine protein kinase receptors

An immunologically mediated reaction to a drug producing stereotyped symptoms unrelated to its pharmacodynamic actions is: A. Hypersensitivity B. Supersensitivity C. Intolerance D. Idiosyncrasy

Description : An immunologically mediated reaction to a drug producing stereotyped symptoms unrelated to its pharmacodynamic actions is: A. Hypersensitivity B. Supersensitivity C. Intolerance D. Idiosyncrasy

Last Answer : A. Hypersensitivity

Higher efficacy of a drug necessarily confers: A. Greater safety B. Therapeutic superiority C. Capacity to produce more intense response D. Cost saving

Description : Higher efficacy of a drug necessarily confers: A. Greater safety B. Therapeutic superiority C. Capacity to produce more intense response D. Cost saving

Last Answer : C. Capacity to produce more intense response

Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Description : Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Last Answer : D. A more potent drug can produce the same response at lower doses